Jessica Fye: Hey there. Good evening. Thanks for taking my question. I have a commercial question on VX-548. I believe that randomized Phase 3 trials have a primary analysis against placebo, but there’s also an opioid comparator arm. How do you think about the commercial implications if the pain efficacy looks better or worse than the opioid arm? Thanks.
Reshma Kewalramani: Jess, this is Reshma. You’re right about the study design. It is a study that has a primary endpoint of VX-548 versus placebo just like the Phase 2 study and there is a secondary endpoint with regard to the opioid comparator arm. And you’ll remember in the Phase 2 study, we also had an opioid arm, but in the Phase 2 program, given the reasonably efficient study design, it was not for comparison, but for context. But I will point you to the press release that we put out to give you if you want to get a sense for what the magnitude of the treatment effect was and how it compares. And I’ll just say that it compares favorably, of course, it was not there for comparison. Let me turn it over to Stuart to comment on the commercial implications.
Stuart Arbuckle: Yes. So Jessica, if you offered people today, a medicine, which had opioid-like efficacy but without all of the associated baggage, including addictive potential, they would tell you that, that is a very, very attractive treatment option for them to be considering. If we were superior to an opioid, then probably that would be additionally beneficial and something that we would obviously be very pleased about. However, I don’t want you to take away anything other than if you have opioid-like efficacy without the baggage, that is a very, very attractive treatment option. And I think that would be a very commercially successful option.
Jessica Fye: Thanks. And if I could just seek a follow-up. Are there any side effects that we should be keeping an eye out for with this mechanism as we approach the Phase 3 readout?
Reshma Kewalramani: Jess, this is Reshma. If you look at the Phase 2 data, both in abdominoplasty and bunionectomy, the benefit risk profile looks very good. And when you look specifically at safety and tolerability, it compares very, very well to placebo. So a really good-looking side effect profile.
Jessica Fye: Thank you.
Operator: The next question will come from Colin Bristow with UBS. Please go ahead.
Colin Bristow: Hey, good afternoon and congrats on the quarter and all the progress. Maybe first on the pipeline and CRISPR-based DMD therapy. Could you give us any more color on the progress of the IND filing? And is it reasonable for us to expect any clinical data in 2024? And then second on VX-880. What should we expect to see at ADA in terms of patient numbers and cohorts? And then just a follow-on from that, with regards to VX-264. Now the IND is cleared, could you give us any more color in terms of the materials or the design of the device? Thank you.
Reshma Kewalramani: Sure, Colin. There were a couple of questions in there. Let me talk about the type 1 diabetes questions first, and then I’ll come back around to DMD. With regard to the type 1 diabetes portfolio at Vertex, we really have three programs. The first is VX-880. That’s the naked cell program that uses off-the-shelf immunosuppressive. That’s the program that has completed, and I’m very pleased to share completed Part A and Part B, and that’s the program where we’re going to share the results at multiple congresses through the year, starting with ADA. What you should expect there is the full cohort of Part A and Part B patients and you should expect that, that is to say more patients’ worth of data than we’ve previously shared and longer-term data, including some patients that are out more than a year.
